News
Press Release | December 4, 2025
Agent Capital Awarded “Partner of the Year” by Penn Center for Innovation, University of Pennsylvania
Press Release | November 19, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.
Press Release | October 28, 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Press Release | October 27, 2025
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Press Release | October 10, 2025
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Press Release | September 30, 2025
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
Press Release | September 17, 2025
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Press Release | September 5, 2025
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Press Release | September 2, 2025
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
Press Release | August 22, 2025
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
Press Release | August 19, 2025
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
Press Release | August 18, 2025
Skyhawk Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
Press Release | August 7, 2025
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
Press Release | August 5, 2025
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
Press Release | July 22, 2025
Orbital Therapeutics Presents Non-Human Primate Data for In Vivo CAR-T Therapy with Potential Best-in-Class Profile for Autoimmune Disease
Press Release | June 17, 2025
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
Press Release | May 28, 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Press Release | May 27, 2025
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
1
2